Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Intermittent fasting may beat daily dieting for belly fat loss

NCT ID NCT05132686

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether intermittent fasting (eating very little two days a week) combined with a Mediterranean diet is better than a daily low-calorie diet for reducing belly fat and liver fat. About 260 adults aged 35-69 with excess belly fat will follow one of two diet plans for 24 weeks. The goal is to see which approach works best for weight loss and improving health markers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 69 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 35-69 years old * BMI between 25-40 kg/m2 * Currently non-smoking * No serious health issues * Fully vaccinated for COVID-19 * Normal blood chemistry profile * East Asian (Chinese, Japanese, Korean), Filipino, Native Hawaiian/other Pacific Islander or white/European ancestry * Non-drinkers / low habitual drinkers, i.e., men ≤15 drinks per week, women ≤10 drinks per week * Volunteers living on the island of Oahu * For peri-menopausal women, the investigators will require that they had their last period at least 1 year before baseline) * DXA VAT ≥90 cm2 for men and ≥80 cm2 for women * Able to read, speak, and write in English Exclusion Criteria: * Pregnancy * Contraindication to MR imaging (e.g. pacemaker, claustrophobia, metal implants) * Previous surgery to remove any part of the small intestine, colon or rectum (e.g. ileostomy or colectomy) or an amputation of a leg or arm. * For women, taking any anti-estrogen medications (e.g tamoxifen, Nolvadex, Istubal, Valodex) * For men, taking any anti-androgen medications (e.g., Eulexin (flutamide); Anandron or Nilandron (nilutamide); Casodex (bicalutamide); Proscar or Propecia (finasteride); Avodart (dutasteride); or bexlosteride, izonsteride, turosteride, episteride). * Diagnosis of Type 1 diabetes or Type 2 diabetes and taking insulin for treatment * Diagnosis of thyroid conditions under treatment with hormones or medications. * Serious health issues such as dialysis, organ transplant, celiac disease, Crohn's disease, chronic liver disease, active case of hepatitis B or C, chronic kidney disease, or any condition that, in the opinion of the investigator, is a contraindication to participation. * Previous problem with fasting blood collection * Cannot exercise (walk) for up to 1hr/day Deferral Criteria : Volunteers with the following conditions will be called back after the specified duration: * Treatments in past 6 months: chemotherapy or radiation of abdomen/pelvis; corticosteroid hormones; prescription weight loss drugs; estrogen/androgen receptor blockers * Substantial weight change (\>20lbs) in past 6 months * Antibiotic use in past 3 months * Colonoscopy, sigmoidoscopy, colon irrigation/bowel cleaning in the past 3 months * MRI/CAT scan with contrast in the past 2 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intra-abdominal fat are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Hawaii Cancer Center

    Honolulu, Hawaii, 96813, United States